|
|
| | L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]- Basic information |
| | L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]- Chemical Properties |
| Boiling point | 1250.5±65.0 °C(Predicted) | | density | 1.375±0.06 g/cm3(Predicted) | | pka | 13.75±0.46(Predicted) |
| | L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]- Usage And Synthesis |
| Uses | MB-VC-MGBA is a agent-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC[1]. | | IC 50 | Duocarmycins | | References | [1] Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. |
| | L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]- Preparation Products And Raw materials |
|
|
Tag:L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]-(932744-62-2)
Related Product Information
|
|
Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-
CL2A-SN-38
DBCO-PEG4-Val-Cit-PAB-MMAF
L-Ornithinamide, N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-1...
PSMA-617
L-Ornithinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-
|